One patient with glioblastoma had PD after 1.27 months while on AMG232 for wild-type TP53 and another patient with glioblastoma harboring a PDGFRA amplification had PD after 7.53 months on dasatinib, everolimus, pazopanib and bevacizumab. The gene discussed is TP53; the disease is glioblastoma.